Ruconest meets Phase III endpoint in BLA-determining trial
This article was originally published in Scrip
The Phase III trial that Pharming and its US partner Santarus were forced to conduct to progress Ruconest (recombinant human C1 inhibitor) for the treatment of acute attacks of angioedema in patients with hereditary angioedema (HAE) has met its primary endpoint.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.